Using fluorescence imaging to improve surgery for liver cancer
Official title: ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery of HCC Patients
Run by Institute of Automation, Chinese Academy of Sciences · NCT06204835 · Data updated 2026-11-12
This study is testing a new imaging technique to help surgeons find liver cancer tumors more easily during surgery, aiming to improve the accuracy of tumor removal for patients.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Institute of Automation, Chinese Academy of Sciences Academic / other |
| Locations | 2 sites (Guangzhou, Guangdong and 1 other locations) |
| Status | Recruiting |
| Started | January 7, 2024 |
| Main results expected | December 31, 2034 |
| Study ends | December 31, 2039 |
| Registry record updated | May 22, 2024 |
| Trial ID | NCT06204835 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 80 diagnosed with hepatocellular carcinoma who are scheduled for hepatectomy and have liver function classified as Child-Pugh A.
✕Probably not a fit
Patients with other malignant tumors, significant organ dysfunction, or those unable to tolerate surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the detection of hepatocellular carcinoma lesions during surgical resection by utilizing NIR-II fluorescence imaging with ITGA6 targeting probes. The investigators will assess whether this innovative imaging technique can increase the intraoperative detection rate of liver tumors, thereby facilitating more accurate surgical removal. The study will also evaluate the safety and effectiveness of the ITGA6 targeting probes for clinical use in patients undergoing hepatectomy.
Why it matters
Potential benefit: If successful, this approach could lead to more precise surgical interventions for liver cancer, potentially improving patient outcomes.
How similar studies have gone: While the use of fluorescence imaging in surgery is an emerging field, this specific approach targeting ITGA6 is novel and has not been extensively tested in previous studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who have been diagnosed with hepatocellular carcinoma. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A. 4. ITGA6 was validated highly expressed preoperatively. 5. Aged 18 to 80, and the expected lifetime is longer than 6 months. 6. Approved to sign the informed consent. Exclusion Criteria: 1. Allergic to Cy7. 2. Enrolled in other trials in the past 3 months. 3. Another malignant tumor was found. 4. Undesirable function of heart, lung, kidney, or any other organs. 5. Unable to tolerate a hepatectomy. 6. The researchers considered inappropriate to be included.
Where it's running
-
Guangdong
Guangzhou, Guangdong, China Recruiting -
Sichuan
Luzhou, Sichuan, China Recruiting
Study contacts
- Principal investigator: Zhenhua Hu, Ph. D — Institute of Automation, Chinese Academy of Sciences
- Study coordinator: Xiaojing Shi, PhD
- Email: shixiaojing2017@ia.ac.cn
- Phone: 13261798652
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.